Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(0.36) per share which met the analyst consensus estimate. This is a 44 percent decrease over losses of $(0.25) per share from the same period last year.
Vuzix Continues To Receive Follow-On And New Design Orders From Multiple Tier-1 Aerospace And Defense Firms
Vuzix® Corporation (NASDAQ:VUZI), ("Vuzix" or, the "Company"), a leading supplier of smart glasses and Augmented Reality (AR) technology and products, announced it has recently received and partially delivered
